These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15860870)

  • 1. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study.
    Feliu J; Escudero P; Llosa F; Bolaños M; Vicent JM; Yubero A; Sanz-Lacalle JJ; Lopez R; Lopez-Gómez L; Casado E; Gómez-Reina MJ; González-Baron M
    J Clin Oncol; 2005 May; 23(13):3104-11. PubMed ID: 15860870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.
    Bajetta E; Procopio G; Celio L; Gattinoni L; Della Torre S; Mariani L; Catena L; Ricotta R; Longarini R; Zilembo N; Buzzoni R
    J Clin Oncol; 2005 Apr; 23(10):2155-61. PubMed ID: 15710946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
    Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.
    Rosati G; Avallone A; Aprile G; Butera A; Reggiardo G; Bilancia D
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):257-64. PubMed ID: 23100174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.
    Hoff PM; Pazdur R; Lassere Y; Carter S; Samid D; Polito D; Abbruzzese JL
    J Clin Oncol; 2004 Jun; 22(11):2078-83. PubMed ID: 15169794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer].
    Guan ZZ; Liu DG; Yu BM; Wu WQ; Shi D; Zhao Y; Wei YQ; Zou LQ; Wu XD; Zhuang W; Feng FY; Zhang P; Yu SY; Xiong HH; Fu Q; Zheng S; Huang JJ; Wu G; Yang CY; Sun SR; Ruan QL
    Zhonghua Zhong Liu Za Zhi; 2004 Feb; 26(2):119-21. PubMed ID: 15059335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
    Petrioli R; Pascucci A; Francini E; Marsili S; Fiaschi AI; Civitelli S; Tanzini G; Battistelli S; Lorenzi M; Roviello F; Francini G;
    Anticancer Drugs; 2008 Jan; 19(1):91-6. PubMed ID: 18043134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
    Lim DH; Park YS; Park BB; Ji SH; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):10-4. PubMed ID: 15782313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.
    Vrdoljak E; Omrčen T; Boban M; Hrabar A
    Anticancer Drugs; 2011 Feb; 22(2):191-7. PubMed ID: 21057306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.
    Comella P; Gambardella A; Farris A; Maiorino L; Natale D; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S;
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):133-9. PubMed ID: 15661564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
    Pierga JY; Fumoleau P; Brewer Y; Zelek L; Martin D; Turpin FL; Goudier MJ; Gil-Delgado M; Baticle JL; Namer M; Chollet P; Sutherland W; Barats JC;
    Breast Cancer Res Treat; 2004 Nov; 88(2):117-29. PubMed ID: 15564795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
    Kotsori AA; Noble JL; Ashley S; Johnston S; Smith IE
    Breast; 2010 Oct; 19(5):377-81. PubMed ID: 20392643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
    Chua D; Wei WI; Sham JS; Au GK
    Jpn J Clin Oncol; 2008 Apr; 38(4):244-9. PubMed ID: 18407933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
    Comella P; Massidda B; Palmeri S; Farris A; Lucia LD; Natale D; Maiorino L; Tafuto S; Cataldis GD; Casaretti R
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):481-6. PubMed ID: 15902461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine-based chemoradiotherapy with adjuvant capecitabine for locally advanced squamous carcinoma of the uterine cervix: phase II results.
    Domingo E; Lorvidhaya V; de Los Reyes R; Syortin T; Kamnerdsupaphon P; Lertbutsayanukul C; Vito-Cruz E; Tharavichitkul E; Jin K; Yoshihara M; Cupino N; Lertsanguansinchai P
    Oncologist; 2009 Aug; 14(8):828-34. PubMed ID: 19661184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.